Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 2/20 | 0.47 |
| ▸ | TXK | P42681 | 14/20 | 0.46 |
| ▸ | ITK | Q08881 | 14/20 | 0.46 |
| ▸ | BTK | Q06187 | 13/20 | 0.46 |
| ▸ | TEC | P42680 | 11/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21303357 | 0.87 | HDAC2 (0.48) | CYP11B2CCR5TXKITKBTK | |
| SCHEMBL21303470 | 0.86 | TXK (0.45) | CYP11B2TXKITKBTKTEC | |
| SCHEMBL19892171 | 0.86 | TXK (0.45) | CYP11B2TXKITKBTKTEC | |
| SCHEMBL21303468 | 0.85 | CYP11B2 (0.44) | CYP11B2CCR5TXKITKBTK | |
| SCHEMBL19892194 | 0.85 | CYP11B2 (0.44) | CYP11B2CCR5TXKITKBTK | |
| SCHEMBL9982687 | 0.82 | OPRM1 (0.60) | CCR5OPRM1OGFRL1OPRD1OPRK1 | |
| SCHEMBL19892449 | 0.82 | ITK (0.64) | TXKITKBTKTEC | |
| SCHEMBL19892362 | 0.81 | NAMPT (0.39) | CYP11B2CCR5TXKITKBTK | |
| SCHEMBL19892305 | 0.81 | TEC (0.41) | CYP11B2TXKITKBTKTEC | |
| SCHEMBL19892436 | 0.80 | SCD5 (0.38) | CYP11B2CCR5TXKITKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752615-B2 | Spirocyclic containing compounds and pharmaceutical uses thereof | GB005, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190263790-A1 | SPIROCYCLIC CONTAINING COMPOUNDS AND PHARMACEUTICAL USES THEREOF | GB005, INC. | 2019-08-29 | — | — | US | disclosed |
| WO-2018032104-A1 | SPIROCYCLIC CONTAINING COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PHARMASCIENCE INC. (CA) | 2018-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752615-B2 | Spirocyclic containing compounds and pharmaceutical uses thereof | TEC, ITK, TXK | CYP11B2 576/4885CCR5 1473/4885TXK 3/4885 |
| US-20190263790-A1 | SPIROCYCLIC CONTAINING COMPOUNDS AND PHARMACEUTICAL USES THEREOF | TEC, ITK, TXK | CYP11B2 576/4885CCR5 1473/4885TXK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.